Quantcast

Latest Cardium Therapeutics Inc. Stories

2014-08-13 08:26:49

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional...

2014-06-24 08:32:14

Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO, June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(®) Ad5FGF-4, Cardium Therapeutics' angiogenic gene...

2014-06-12 08:30:19

SAN DIEGO, June 12, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx(®) angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center...

2014-05-22 08:30:50

SAN DIEGO, May 22, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company's presentation by CEO Christopher J Reinhard is scheduled to begin at 3:00 p.m. ET and will be available at Taxus Cardium's website at...

2014-05-15 08:33:45

SAN DIEGO, May 15, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results for the quarter ended March 31, 2014. http://photos.prnewswire.com/prnvar/20051018/CARDIUMLOGO As recently announced, our Cardium Therapeutics operating unit is focused on the clinical and commercial development of advanced regenerative therapeutics that includes the Generx(®) [Ad5FGF-4] product candidate, and Excellagen(®) an...

2014-05-12 08:33:04

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced that the Company's Excellagen(®) flowable dermal matrix in combination with Orbsen Therapeutics' mesenchymal stromal stem cell therapy Cyndacel-M(TM) has been selected for clinical evaluation in a Phase 1b safety study for the potential treatment of chronic diabetic wounds to be funded by the European Union under EU Framework 7 (FP7). The project, known by the...

2014-03-17 08:29:58

SAN DIEGO, March 17, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd. http://photos.prnewswire.com/prnvar/20140317/LA83695LOGO The strategic collaboration is designed to support the commercial development of Generx(®) and...

2014-03-03 08:32:55

SAN DIEGO, March 3, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®,...

2014-01-27 08:28:34

SAN DIEGO, Jan. 27, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx(®) Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen(®) for wound healing and as a biologics delivery platform. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Based on these...

2014-01-24 08:24:29

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- As previously reported, Cardium Therapeutics, an advanced regenerative therapeutics company, today announced that its common stock will begin trading on the OTCQB Marketplace under the ticker symbol "CRXM" commencing on Friday, January 24, 2014. The move to the OTCQB Marketplace does not change Cardium's reporting obligations under applicable laws. Accordingly, Cardium expects to continue to file its Quarterly Reports on Form 10-Q, annual...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related